JAGSONPAL PHARMACEUTICALS
|
JAGSONPAL PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 8.50 | 10.20 | 7.20 | 6.51 | 3.00 |
| CEPS(Rs) | 9.13 | 10.66 | 7.78 | 6.93 | 3.44 |
| DPS(Rs) | 5.00 | 5.00 | 4.00 | 1.00 | 0.50 |
| Book NAV/Share(Rs) | 64.43 | 57.30 | 50.68 | 43.55 | 39.39 |
| Tax Rate(%) | 24.79 | 23.24 | 29.23 | 22.01 | 16.40 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 10.28 | 13.28 | 10.32 | 10.15 | 5.38 |
| EBIT Margin(%) | 13.68 | 13.70 | 11.11 | 11.91 | 6.26 |
| Pre Tax Margin(%) | 13.31 | 13.54 | 10.99 | 11.64 | 5.94 |
| PAT Margin (%) | 10.01 | 10.39 | 7.78 | 9.08 | 4.96 |
| Cash Profit Margin (%) | 10.75 | 10.86 | 8.41 | 9.65 | 5.68 |
| Performance Ratios | |||||
| ROA(%) | 10.49 | 14.29 | 11.24 | 10.90 | 5.53 |
| ROE(%) | 14.02 | 18.89 | 15.28 | 15.70 | 7.88 |
| ROCE(%) | 17.72 | 24.15 | 21.23 | 19.43 | 9.46 |
| Asset Turnover(x) | 1.05 | 1.38 | 1.44 | 1.20 | 1.11 |
| Sales/Fixed Asset(x) | 10.09 | 5.65 | 4.10 | 3.18 | 2.80 |
| Working Capital/Sales(x) | 1.38 | 1.88 | 2.95 | 2.35 | 2.57 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.10 | 0.18 | 0.24 | 0.31 | 0.36 |
| Receivable days | 25.88 | 25.87 | 21.26 | 33.13 | 48.57 |
| Inventory Days | 29.02 | 35.78 | 44.76 | 57.34 | 71.38 |
| Payable days | 55.17 | 69.43 | 75.08 | 67.24 | 76.56 |
| Valuation Parameters | |||||
| PER(x) | 32.94 | 28.42 | 43.57 | 12.22 | 5.81 |
| PCE(x) | 30.67 | 27.20 | 40.31 | 11.49 | 5.08 |
| Price/Book(x) | 4.34 | 5.06 | 6.19 | 1.83 | 0.44 |
| Yield(%) | 1.79 | 1.72 | 1.28 | 1.26 | 2.87 |
| EV/Net Sales(x) | 2.84 | 2.72 | 3.66 | 0.82 | 0.07 |
| EV/Core EBITDA(x) | 18.30 | 16.17 | 27.99 | 6.60 | 1.05 |
| EV/EBIT(x) | 19.29 | 18.31 | 29.57 | 6.92 | 1.17 |
| EV/CE(x) | 3.16 | 4.06 | 4.65 | 0.94 | 0.08 |
| M Cap / Sales | 3.55 | 3.21 | 3.78 | 1.11 | 0.29 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -11.83 | 8.79 | 15.77 | 18.53 | -4.95 |
| Core EBITDA Growth(%) | -18.90 | 40.18 | 21.22 | 112.25 | 2.74 |
| EBIT Growth(%) | -12.89 | 30.81 | 20.29 | 125.46 | 1.85 |
| PAT Growth(%) | -15.94 | 41.72 | 10.53 | 116.73 | 9.07 |
| EPS Growth(%) | -16.70 | 41.72 | 10.53 | 116.73 | 9.08 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | 0.06 | 0.06 |
| Current Ratio(x) | 6.90 | 4.89 | 3.40 | 2.98 | 2.79 |
| Quick Ratio(x) | 6.35 | 4.31 | 2.53 | 2.25 | 1.94 |
| Interest Cover(x) | 37.69 | 85.28 | 94.48 | 43.59 | 19.31 |
| Total Debt/Mcap(x) | - | - | - | 0.03 | 0.14 |
Compare Financial Ratios of peers of JAGSONPAL PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| JAGSONPAL PHARMACEUTICALS | ₹1,743.2 Cr | -6.1% | 11.2% | 71.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹433,920.0 Cr | -0.1% | 1.7% | 45.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹155,160.0 Cr | -0.1% | -2.2% | 56.9% | Stock Analytics | |
| CIPLA | ₹118,917.0 Cr | 1.7% | 0.5% | 23.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,017.0 Cr | 5.7% | 12.4% | 18.5% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹97,997.1 Cr | -1.4% | 3.1% | 44.8% | Stock Analytics | |
JAGSONPAL PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| JAGSONPAL PHARMACEUTICALS | -6.1% |
11.2% |
71.7% |
| SENSEX | -5% |
0.6% |
9.2% |
You may also like the below Video Courses
